Insulin degludec/liraglutide versus its monotherapy on T2D patients: A lifetime cost-utility analysis in China
Work
Year: 2022
Type: article
Abstract: Introduction: IDegLira (brand name Xultophy) is a novel fixed ratio combination of insulin degludec and liraglutide for type 2 diabetes (T2D) patients. This study aimed to investigate the lifetime cos... more
Source: Frontiers in Pharmacology
Institutions First Affiliated Hospital of Guangdong Pharmaceutical University, Shenyang Pharmaceutical University, Shanghai First People's Hospital, Shanghai Jiao Tong University, Nanfang Hospital +1 more
Cites: 43
Cited by: 3
Related to: 10
FWCI: 0.695
Citation percentile (by year/subfield): 66.98
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: gold
APC paid (est): $2,950